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TITLE:  MRI PHASE CONTRAST  FLOW VELOCITY IMAGING OF 
MAIN   PULMONARY ARTERY 
OBJECTIVE :  
To assess the pulmonary arterial flow parameters  using phase contrast 
magnetic resonance imaging. To correlate the size of the main pulmonary 
artery as measured using spiral computerised tomography  with the flow 
parameters as measured using phase contrast MRI and also with ECHO 
parameters. 
MATERIALS & METHODS: 
Studies were performed with a 1.5-T clinical magnet Magnetom 
symphony; Siemens Medical Solutions. Prospective study , study size - 
50 subjects. After informed written consent, all subjects who had 
pulmonary artery size more than 2.9cm underwent phase contrast flow 
velocity imaging  which includes in plane and through plane imaging. 
Mean VENC value  for main pulmonary artery  is kept between 75-100 
cm/sec. Patients ECHO findings reviewed. Normal subjects with 
pulmonary artery size less 2.9cm also included in the study. 
RESULTS: 
37 subjects who had  pulmonary artery (PA) size more than 2.9cm had 
pulmonary artery average velocity less than 11.7cm/sec and minimum 
pulmonary artery area more than 10.5 cm
2 , 
measured using phase contrast 
flow velocity imaging.  
Degree of correlation ( 86.5%) is higher between pulmonary artery(PA) 
size & Pulmonary artery average velocity  and also between PA 
minimum area & PA average velocity (89.5%).  
 
CONCLUSION: 
The pulmonary artery size criteria for pulmonary hypertension is well 
correlated with PA average velocity and  PA average area . 
MRI Phase contrast imaging is a novel non invasive imaging modality 
that can be used in the diagnosis of  Pulmonary arterial hypertension by 
means of measuring flow parameters. 
 
Key words:  Pulmonary arterial hypertension, 
MRI,CT,ECHO,pulmonary artery average velocity,pulmonary artery size. 
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INTRODUCTION 
Pulmonary hypertension is a disease which is characterized by 
increased pulmonary arterial pressure and pathologic changes in 
precapillary pulmonary arteries. It is a progressive disease. Pulmonary 
arterial hypertension is defined as an elevation in mean pulmonary 
arterial pressure above 30 mmHg during exercise and 25 mmHg at rest. 
Arterial pressure may be considered as a function of blood flow and 
vascular resistance. Vascular resistance depends upon the cross-sectional 
area of the vascular bed. The pulmonary vessels are more compliant than 
their systemic counterparts owing largely to their thin walls and also  
their larger diameter. Furthermore, the pulmonary bed can also respond to 
increasing flow by opening up additional vascular channels. 
Numerous classification schemes have been developed to 
categorize the causes of pulmonary hypertension. One method has been 
to examine the disease from a physiologic perspective, using the relations 
among pressure, pulmonary vascular resistance, and pulmonary flow. In 
this type of classification, diseases that cause increased resistance, 
increased flow, or increased pulmonary vascular pressure are grouped 
separately. The World Health Organization has classified pulmonary 
hypertension into pulmonary arterial hypertension, pulmonary venous 
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hypertension, pulmonary hypertension secondary to hypoxemia/ 
respiratory disease, pulmonary hypertension secondary to 
thromboembolic disease, and pulmonary hypertension secondary to 
processes affecting the pulmonary vasculature directly. Other 
investigators have classified pulmonary arterial hypertension into pre-and 
postcapillary etiologies.“Presenting symptoms included dyspnea (60%), 
fatigue (19%), and syncope (or near syncope) (13%)” (Stuart rich et al1 ) 
Generally it is grouped in to five categories 
1. Pulmonary arterial hypertension (PAH) 
2. Pulmonary hypertension due to left heart disease 
3. Pulmonary hypertension due to lung diseases  
4. Pulmonary hypertension due thrombus/embolism 
5. Pulmonary hypertension with miscellaneous cause 
             Echocardiography is the intial mode of investigation of choice. 
PH due to left heart disease (group 2) is effectively investigated with 
echocardiography and accounts for the majority of pulmonary 
hypertensive patients. If a non-cardiac cause is suspected, a series of 
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systemic investigations is performed including pulmonary function tests, 
sleep studies, ventilation perfusion scanning and serological markers. 
Computerised tomography (CT) diagnoses pulmonary 
hypertension depending on the size criteria of the main pulmonary artery. 
Size of main pulmonary artery  > 29mm is sensitive , size of main 
pulmonary artery > 35mm is specific. CT also useful in detecting lung 
parenchymal due to pulmonary hypertension and primary lung disease if 
any that would have caused pulmonary hypertension. 
Magnetic Resonance Imaging (MRI)  also plays an important role 
in the diagnosing and monitoring the patients with pulmonary 
hypertension. Phase contrast MRI is a novel non invasive modality of 
choice which measures the number of flow parameters like peak and 
average  velocity , average and minimum area of the main pulmonary 
artery which helps in the diagnosis of pulmonary hypertension. 
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REVIEW OF LITERATURE 
ANATOMY AND PHYSIOLOGY OF THE  
PULMONARY CIRCULATION 
 
 
 
 
 
 The main pulmonary artery origins from the right ventricle at  the 
level of the pulmonary valve and  runs approximately 5 cm before 
bifurcating into the left and right branches.Pulmonary artery carries  
deoxygenated blood from the right ventricle to the lungs for oxygenation.   
The right pulmonary artery passes anterior to the right main bronchus and 
divides into the truncus anterior, which extends into the right upper lobe 
of the lung, and the interlobar branch, which divides into segmental 
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arteries extending into the right middle and right lower lobes. The left 
pulmonary artery is shorter vessel and passes cephalad to the left main 
bronchus; it continues as an interlobar artery and extends into the left 
upper and lower lobes of the lung through segmental branches. 
 
Pulmonary circulation : Blue –Pulmonary artery ; Red –Bronchial artery 
 
The pulmonary circulation consists of two parallel networks: the 
pulmonary arterial circulation and the bronchial arterial circulation. 
Pulmonary arteries course along the lobar, segmental, and subsegmental 
airways to the level of the terminal bronchioles. Small pulmonary arteries 
from the subsegmental level to the terminal bronchioles possess a thick 
muscular media, and range from 50 to 1000 µm in size. These small 
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pulmonary arteries progressively lose much of their muscle within the 
arteriolar media as well as their external elastic membrane.  
By the level of the respiratory bronchioles and alveolar ducts they 
are termed pulmonary arterioles, and range in size from 10 to 150 µm. 
These vessels ramify  further within the alveolar walls to form a rich 
capillary network. Capillary blood collects in venules, which coalesce 
progressively to form veins, which course within the interlobular septa, 
eventually to empty into the left atrium. 
 Bronchial arteries, averaging two per lung, course within the 
pulmonary hila along the mainstem bronchi to the level of the terminal 
bronchiole, and form a plexus that extends from the adventitia through to 
the submucosa of the associated airway. Bronchial arteries freely form 
anastomoses with pulmonary arteries, primarily at the capillary and 
postcapillary levels. 
Unlike the tracheobronchial system, in which the major component 
to air-flow resistance is located within the large airways, the major site of  
resistance to pulmonary arterial blood flow is located at the small  
muscular pulmonary arterial and arteriolar level. 
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Caliber changes in  the vessels at this level regulate pulmonary 
arterial pressure and are critical for optimizing ventilation and perfusion 
matching. 
The pulmonary circulation is a low pressure system—the mean 
arterial pressure is approximately one sixth that of the systemic 
circulation. This low pressure is maintained at a relatively consistent 
level even with large increases in pulmonary blood flow such as may 
occur with exercise. This is possible because when the body is at rest, 
numerous pulmonary capillaries normally are not perfused; these 
capillaries are “recruited” when increased pulmonary blood flow must be 
accommodated. 
Normal pressure values in pulmonary circulation 
 
Central venous pressure 3–8 mmHg 
Right ventricular pressure 
systolic 15–30 mmHg 
diastolic 3–8 mmHg 
Pulmonary artery pressure 
systolic 15–30 mmHg 
diastolic 4–12 mmHg 
Pulmonary vein/ 
Pulmonary capillary wedge pressure 
2–15 mmHg 
Left ventricular pressure 
systolic 100–140 mmHg 
diastolic 3-12 mmHg 
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PATHOGENESIS 
Pulmonary hypertension is defined as a pulmonary systolic arterial 
pressure equal to or exceeding 25 mmHg at rest or 30 mmHg with 
exercise, or a mean pulmonary arterial pressure equal to or exceeding 18 
mmHg (National Institutes of Health (NIH) registry of patients with 
primary pulmonary hypertension) (Yoshiharu Ohno  et al2). Pulmonary 
venous hypertension is present when pulmonary venous pressure, usually 
approximated by measurement of the pulmonary capillary wedge 
pressure, is equal to or exceeds 18 mmHg.  
 
 
 
  
TPG, Transpulmonary pressure gradient (MPAP _ mean PCWP). 
Values are measured at rest (Galie et al
3
) 
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Several mechanisms may produce a decrease in the total number of 
small pulmonary arteries, thereby increasing pulmonary vascular 
resistance and producing elevated pulmonary arterial pressure. These 
mechanisms include intraluminal arterial occlusion, muscular contraction 
of small pulmonary arteries, vascular remodeling with wall thickening, or 
conditions that produce pulmonary venous hypertension.  
Several of these mechanisms may be operative simultaneously in a 
patient with pulmonary hypertension. 
The pulmonary vascular endothelium responds to changes in 
oxygen tension, transmural pressure, and pulmonary blood flow, and 
participates actively in the regulation of pulmonary arterial pressure 
through the elaboration of various vasoactive substances, such as 
prostacyclin, nitrous oxide, and endothelin. The agents have a direct 
effect on pulmonary vascular smooth muscle tone (promoting relaxation 
and vasodilation), and also may directly affect platelet function.  
Abnormalities in endothelial cell function or injuries to these cells 
may be the fundamental derangement that ultimately produces the 
structural vascular changes observed in patients with pulmonary 
hypertension. 
15 
 
 
Various histopathological abnormalities may be observed in 
patients with pulmonary hypertension, varying somewhat depending on 
the cause of hypertension. In general, regardless of the specific cause of 
the pulmonary hypertension, the pulmonary arteries become dilated, 
occasionally to the point of being considered aneurysmal. Pulmonary 
arterial atherosclerosis, although occasionally present to a mild degree in 
the larger pulmonary arteries of normal adults, often is extensive in 
patients with pulmonary hypertension and commonly involves small 
arteries.  
Pulmonary hypertension-related pulmonary arterial atherosclerosis 
pathologically appears similar to atherosclerosis in systemic arteries, 
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although complicating features, such as necrosis, ulceration, and 
calcification, are relatively uncommon. Thickening of the muscular 
media of small pulmonary arteries is a common feature in many causes of 
pulmonary hypertension, and usually results from a combination of 
muscular hyperplasia and hypertrophy. Often, extension of muscular 
tissue into arterioles that normally contain no muscle, or “arterialization,” 
may be observed in patients with pulmonary arterial hypertension. 
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The term pulmonary plexogenic arteriopathy refers to a 
constellation of histopathological vascular changes that often is 
encountered in patients with primary pulmonary hypertension, but it also 
may be seen in patients with pulmonary hypertension of other etiologies, 
such as hepatic disease, connective tissue disorders, congenital 
cardiovascular disease, and some medication prescribed for weight loss.  
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PULMONARY PLEXOGENICARTERIOPATHY 
Histopathological features present in pulmonary plexogenic 
arteriopathy include a combination of fibrinoid necrosis, dilation lesions, 
plexiform lesions, intimal fibrosis, and vasculitis. Plexiform lesions affect 
small muscular arteries ranging in size from 100 to 200µm, usually near 
vascular branch points, and consist of a focally dilated muscular vessel 
with a disrupted internal elastic membrane that contains very narrow 
vascular channels interspersed with fibroblasts and connective tissue. 
Plexiform lesions are characteristic of prolonged severe pulmonary 
hypertension. 
GRADING OF PULMONARY HYPERTENSION 
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APPROACH TO PULMONARY HYPERTENSION 
(Nazzareno Galie et al
4
) 
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ROLE OF ECHOCARDIOGRAPHY 
Echocardiography is a vital screening test in symptomatic patients 
at risk for Pulmonary Hypertension. It  measures the pressure in the 
pulmonary vessels and also used to exclude cardiac cause for pulmonary 
hypertension. As an investigation modality, it has the advantage of being 
widely available, non invasive technique and cost effective.  
Echo parameters include qualitative assessment of right 
ventricle, which is assessed by parasternal long-axis, short-axis and the 
apical four-chamber views. Dilated right atrium , right ventricle 
frequently seen. D- shaped interventricular septum is pathognomic. Right 
ventricular hypertrophy is seen but dilatation is more common. Right 
ventricular hypertrophy is defined by a wall thickness of  more than 
0.7cm on the apical four-chamber view. Hypertrophy of moderator band 
will also be  seen. Dilatation of tricuspid annulus and dilated main 
pulmonary artery is noted classically. 
Regional wall motion abnormalities, contractility assessment of 
right ventricle can be done in patients with pulmonary hypertension. 
(Luke S. Howard et al
5
) 
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TRPG , tricuspid regurgitant pressure gradient measurement 
plays important role in the diagnosis and grading the degree of 
pulmonary hypertension. And depending on the values it is divided in to 
mild , moderate and severe. Value  <25mmHg is normal, > 25mmHg is 
suspicious for pulmonary hypertension, 30-40 mild , 40-60 moderate, >60 
severe. 
Pulmonary valve motion abnormalities can be assessed in the 
echocardiography. In M mode echocardiography following features are 
seen in a case of pulmonary hypertension  presence or  absence and the 
amplitude of the “a” wave, magnitude of the e-f slope, fluttering of the 
posterior pulmonic leaflet presence of mid-systolic closure or notching,  
“TAPSE, Tricuspid annular plane systolic excursion is the 
reflection of the movement of base to apex shortening of the RV in 
systole and can be derived from the four-chamber view .When measuring 
TAPSE, it is important to ensure that the entire RV is included in the 
view, in particular that there is no dropout in the endocardial outline 
along the IVS and RV free wall. Maximal TAPSE is defined by the total 
excursion of the tricuspid annulus from its highest position after atrial 
ascent to the peak descent during ventricular systole (Kaul S et al
6
) .”  
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“A TAPSE of <15 mm is associated with a   significantly higher risk 
of mortality compared with a TAPSE of  > 15 mm (Ghio S et al
7 
)  and 
TAPSE is recommended by treatment guidelines as a prognostic indicator 
in PAH for the assessment of disease severity and response to therapy.” 
And Value of > 20mm is normal. 
Many other parameters like right atrial volume index, inferior vena 
cava diameter etc ., can be measured. 
And also to look for secondary cause of pulmonary hypertension 
like left ventricular dysfunction, left heart valve disease, congenital heart 
disease echocardiography plays important roll. 
 Transoesophageal echocardiography can be done. 
ROLE OF RADIOGRAPH AND CT 
The pulmonary arterial hypertension  is characterised by  dilation 
of the pulmonary arteries with abrupt tapering of the peripheral 
pulmonary vessels. This is the universal features in all etiology of the 
pulmonary hypertension. 
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Chest radiography shows enlargement of the main pulmonary 
artery segment and dilation of the right and left interlobar pulmonary 
arteries. Diameter of interlobar pulmonary artery at the level bronchus 
intermedius, exceeds 15 mm in women and 16 mm in men is 
characteristic for pulmonary hypertension . The left pulmonary artery is 
best measured from the orifice of the left upper lobe bronchus to the 
posterior aspect of the vessel if it exceeds 18 mm, pulmonary 
hypertension probably is present. 
The upper  limit for a normal main pulmonary artery  on axial CT 
or MR images is 29 mm. When the main pulmonary artery segment 
exceeds 29mm, pulmonary hypertension is usually suspected. However , 
pulmonary hypertension may be present in patients with a normal sized 
main pulmonary arterial segment. If the main pulmonary artery is visibly 
larger than the aorta, elevated pulmonary pressures usually are present. 
Radiographically, right atrial and ventricular enlargement, 
enlargement of the main  pulmonary arteries  and tapering of peripheral 
arterial branches termed ‘peripheral pruning’—are seen. In chronic cases 
the main pulmonary arteries may develop calcification due to atheroma. 
Central arterial enlargement may mimic enlarged hilar lymph nodes. It  is 
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differentiated by the feature that lymphadenopathy characteristically has 
a lobulated border whereas arterial enlargement has a smoother outline.  
A recognized method of assessing pulmonary arterial size is by 
measuring the size of the right descending pulmonary artery. 
Enlargement may be diagnosed if the transverse diameter of the artery at 
its midpoint is greater than 17 mm. Overall, although relatively specific, 
the sensitivity of chest radiography for the diagnosis of PAH is low 
 
When pulmonary hypertension is prolonged and severe, 
calcification of the pulmonary arteries, usually affecting the main, right, 
or left pulmonary arteries, and, less commonly, the lobar pulmonary 
arteries, may be present. This finding usually, but not invariably, is 
associated with irreversible vascular disease. 
Chest radiograph demonstrates 
gross dilatation of the main, left 
and right pulmonary arteries in 
a patient with Eisenmenger 
atrial septal defect. 
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Although chest radiography and CT scanning often may suggest 
the presence of pulmonary hypertension, echocardiography is the 
examination most commonly used for noninvasive assessment of possible 
pulmonary hypertension. Echocardiography, using continuous wave or 
pulsed Doppler, provides noninvasive measurement of pulmonary arterial 
pressures and also allows detailed morphologic evaluation of the right 
ventricle.  
As pulmonary venous pressure rises, the upper lobe veins distend. 
They initially reach the size of, and eventually become larger than, the 
lower lobe vessels (thus reversing the normal ‘gravity-dependent’ 
pattern). This is described as ‘upper lobe venous diversion’ and is often 
the first recognized radiological sign of pulmonary venous hypertension . 
If the pulmonary venous pressure continues to rise and exceeds the 
plasma oncotic pressure, fluid will begin to accumulate in the lung 
interstitium. This is known as interstitial pulmonary oedema. 
Radiologically this is associated with the appearance of interstitial 
(Kerley B) lines. These lines were first described in 1933 ( kerley .p
8
) 
and represent thickening of interlobular septa  within the lung. They were 
originally classified into three groups: 
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1. Kerley A lines are  4 cm in length seen in the upper and mid portions 
of the lung. These deep septal line  radiate from the hilum to the 
central part of the lungs but do not reach the periphery / pleura. These 
lines suggest more acute or severe degree of edema. 
2. Kerley B lines are short measuring 1 cm or less interlobular septal 
lines, seen in  the  periphery of lower zones, parallel to each other and 
at 90 degree to the pleural surface. 
3. Kerley C lines are now seen to overlap Kerley B lines. It is no longer 
used now (Heitzman ER
9
) 
 
 
 
 
 
 
A-Upper lobe venous congestion  B-Thickened interlobular septae; 
kerley b 
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Certain patterns of opacification may suggest particular diagnoses. 
The often cited ‘perihilar bat's wing’ pattern of airspace consolidation is 
seen most commonly in left ventricular and renal failure, whereas 
alveolar oedema localized to the right upper zone is suggestive of severe 
mitral regurgitation. The latter is thought to be a result of predominant 
regurgitant blood flow in the right upper lobe pulmonary vein, from the 
superiorly and posteriorly positioned mitral valve. 
Computed tomography (CT) findings in pulmonary oedema 
include thickening of septal and bronchovascular structures. In addition, 
perihilar ground-glass opacity may be found in cases of mild 
parenchymal oedema. Alveolar oedema may initially be recognized as 
peribronchovascular airspace nodules progressing to dense airspace 
consolidation. 
In chronic pulmonary venous hypertension signs of pulmonary 
arterial hypertension may also develop. In addition, a fine nodular pattern 
may appear throughout both lungs. These nodules represent haemosiderin 
deposition. This pattern was previously most commonly seen in patients 
with long-standing severe mitral stenosis. In very severe chronic PVH 
pulmonary ossicles (up to 1 cm in size) may develop 
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Chest radiography in patients with Primary Pulmonary 
Hypertension shows enlargement of the main, right, and left pulmonary 
arteries, often with enlargement of the right ventricle and right atrium. 
High-resolution CT (HRCT) may show that the peripheral pulmonary 
arteries are substantially larger than usual.  
Attempts have been made to correlate the stage of radiographic 
pulmonary venous hypertension with pulmonary venous pressure (as 
measured by the pulmonary capillary wedge pressure [PCWP]) 
(10,11,12). When the PCWP is normal (8–12 mmHg) the chest 
radiograph is not expected to demonstrate any specific abnormality 
related to pulmonary venous pressure. Mild PCWP elevation (12–18 
mmHg) is associated with upper lobe venous distension. Further PCWP 
increase (19–25 mmHg) leads to interstitial oedema (peribronchial 
cuffing, Kerley lines). Above this value (25 mmHg) airspace opacities are 
seen. Although not accurate, these correlates serve to give an 
approximation of intravascular pressure. 
Although most cases of PVH are associated with valvular and/or 
myocardial dysfunction leading to cardiomegaly, this is not always the 
case. An important example of this is in the early post-myocardial 
infarction phase. Here, up to 50% of patients have been shown to exhibit 
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radiographic signs of PVH in the first 24–48h post infarction (Higgins 
CB et al
13,14
). This is due to an acute decrease in myocardial compliance 
which essentially resolves in the first week post infarction. The other 
situation where signs of pulmonary oedema may be seen with a normal 
heart size is non cardiogenic pulmonary oedema. 
High-resolution CT may demonstrate inhomogeneous lung opacity, 
representing the presence of differential pulmonary parenchymal 
perfusion. The regions of decreased pulmonary parenchymal attenuation 
represent areas of mosaic perfusion, and the vessels in these regions of 
lung often are visibly smaller than their counterparts in regions of 
increased lung attenuation. Although airway diseases may result in a 
similar pattern of mosaic perfusion, vascular and airway causes of mosaic 
perfusion may be distinguished using postexpiratory imaging. When due 
to airway diseases, differences in lung attenuation become accentuated 
with post expiratory imaging, whereas a proportional increase in 
attenuation in areas of both increased and decreased attenuation is 
expected for patients with pulmonary vascular disease. 
“A prospective study (Alhamad EH et al 
15
) in which the subjects 
were 134 patients who underwent rightheartcatheterization and chest CT 
within 72hours of each other showed that CT-derivedmeasurement of the 
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MPA diameter has strongercorrelation with the presence of 
pulmonaryhypertension in patients without ILD (MPAdiameter > 31.6 
mm had a positive predictivevalue of 90.0% and a negative predictive 
valueof 58.3%) than in patients with ILD (MPA diameter> 25 mm had a 
positive predictive valueof 46.3% and a negative predictive value 
of83.8%). In both groups, however, the MPA diameterwas significantly 
greater in patients withpulmonary hypertension than in those without” 
A number of findings on CT have been shown to be useful in 
evaluating possible PAH. A ratio of pulmonary artery diameter to aortic 
diameter of >1 has been shown to correlate with elevated mean PAP, 
although a ratio of <1 does not exclude PAH. In a study by Kuriyama et 
al
15
, a main pulmonary artery diameter of  more 29 mm was shown 
to have a sensitivity of 69% and specificity of 100% for predicting 
PAH. Main pulmonary artery diameter has been shown to be useful for 
detecting PAH in patients with advanced lung disease, with a sensitivity 
of 87% and specificity of 89%, with the additional finding that a 
segmental artery-to-bronchus ratio >1:1 increases specificity 
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RIGHT HEART CATHETERIZATION 
It is generally known as pulmonary artery catheterisation or Swan-
Ganz catheterisation. It is the gold standard modality in diagnosing and 
evaluating  pulmonary hypertension. Echocardiography is very useful 
screening tool for the presence of pulmonary hypertension, but it only 
gives an measure of right ventricular systolic pressure. 
CATHETER 
 
Catheter 
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 The catheter is usually 120 cm length and has multiple lumens . 
 A small inflatable balloon  is located at the tip of the catheter. It is  
inflated so that it can “float”  in the direction of blood flow . 
 Thermistor (temperature indicator) is present  at the tip of the 
catheter; it  detects the  changes in blood temperature when 
performing thermodilution cardiac output measurement 
 
CHOICE OF VENOUS ACCESS SITES 
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 Right internal jugular vein is used. 
 Initially , for a patient’s initial catheterization, femoral veins are 
used for catheterization, as it allowed the greatest flexibility 
especially for left heart catheterisation. 
  In patients for whom it is tough to advance the catheter into the 
pulmonary artery due to increased pulmonary arterial pressures, the 
right internal jugular approach may be superior than inferior vena 
cava approach. This is because this approach allows the catheter to 
form a natural curve on the floor of the right ventricle it points 
upward into the main pulmonary artery. 
 
STANDARD RIGHT-HEART CATHETERIZATION 
MEASUREMENTS 
 
o right atrial pressure (RAP) 
o right ventricular pressure (RVP) 
o pulmonary arterial pressure (PAP) 
o pulmonary capillary wedge pressure (PCWP) 
o systemic arterial pressure (BP) and heart rate 
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o cardiac output (CO) 
o pulmonary arterial vasoreactivity 
o pulmonary arterial (PA)  saturation 
o superior vena cava (SVC)& IVC saturation 
o right atrial (RA)& RV saturation 
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Normal pressure waveforms in right heart catheterisation 
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Risks in central venous catheterization : 
 It is highly invasive 
 As the lung is close to the major veins of the neck. The needle 
could pierce the lung it can cause pneumothorax and collapse of 
the lung 
 Patient discomfort canresult from  placement of the catheter and 
when it is inserted.. 
  Any catheter entering the body can be a source of bacteria and 
infect the patient. 
 Bleeding occurs around holes in the veins but it is mild and seals 
on its own  . As the major arteries run alongside the major veins, 
unknowningly arteries can be punctured . It is usually self limiting 
but sometimes it can cause hemomediastinum which is a life 
threatening condition. 
  Blood clots can commonly form in catheters inside the veins. Such 
clots usually do not cause any  problems. Sometimes, clots can 
travel  into the lungs causing  pulmonary embolism.  
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  Rarely, air enters the catheter  travel through the heart and cause 
lung injury and cause air embolism.  
Some risks are specific to the placement of the catheter through the 
heart to the pulmonary artery. 
 Rupture of the pulmonary artery – It is  very rare complication. 
It can cause life-threatening bleeding 
 Heart rhythm abnormalities - The catheter can accidentally 
tickle the heart and stimulate, causing arrhythmia. 
ROLE OF MRI 
MRI is a novel ,non invasive method of imaging heart 
morphology and its functions. Cardiac MRI helps assessing morphology 
of the heart like  wall movement, valve movement ,  blood vessels (aorta, 
pulmonary vein, coronary artery). Function of the heart like  blood 
volume ,flow, cardiac output can be analysed. It measures hemodynamic 
parameters in pulmonary hypertension patients which helps in diagnosing 
as well as in monitoring the disease process and its severity. 
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Cardiac MRI is used to measure the  hemodynamic parameters in 
the pulmonary hypertension patients which helps in the diagnosis as well 
as post treatment follow up and monitoring of the disease. (Peacock  
AJ et al
16
 ) 
MRI is a useful modality for visualising right ventricular anatomy , 
function which plays important role in the prognosis of patients with 
pulmonary hypertension.Contrast MRI clearly depicts the myocardial 
scarring due to infarct, infection and infiltration and infiltrative pathology 
of myocardium by means of showing delayed enhancement as these 
pathology can be seen associated with pulmonary hypertension. 
Like echocardiography, MRI can also quantify flow velocity with 
in the vessels by means of phase contrast flow velocity imaging. 
Advantages of MRI compared with the echocardiography is there is no 
limitation in choosing the arbitrary plane of imaging, whereas in 
echocardiography because of inadequate acoustic window we may not be 
able to choose the arbitary plane of imaging. Thus as we can choose 
arbitrary plane of imaging in MRI it has a greater accuracy and 
reproducibility as compared with the echocardiography(Shah DJ et al
17
). 
More over in echocardiography diagnosis of pulmonary hypertension is 
made with  parameter like TRPG ( tricuspid regurgitant pressure 
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gradient) which is the indirect measurement of pulmonary hypertension 
in echocardiography. Whereas in MRI using phase contrast flow velocity 
imaging we are able to measure the velocity directly  in the pulmonary 
artery. 
MRI is considered as standard modality of choice for assessment of 
congenital heart disease as it gives very good information about the 
structure changes , situs , septal defects , atrio ventricular concordance, 
vessel diameter , wall motion, valvular stenosis  / regurgitation.( 
Landzberg MJ
18
) 
MRI has many advantage over CT and echocardiography. There is 
no ionising radiation , thus allowing repeated examination whenever 
necessary without the effect of cumulative radiation exposure. MRI has 
superior resolution in delineating the  soft tissue contrast and has higher 
spatial resolution than echocardiography. Tailored study of the heart and 
great vessels using Cardiac MRI and MR angiogram.( McLure LE  
et al
19
) 
Imaging  sequences used for cardiac MR can be broadly divided in 
to dark blood technique and bright blood technique . Dark blood 
sequences are basically spin echo sequences that show flowing blood as 
flow void it includes conventional spin echo, breath hold turbo or fast 
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spin echo and double inversion recovery fast spin echo. They are static 
images which show anatomy and myocardial viability. As the signal from 
moving blood is very low it appears black.  
Bright blood sequences are gradient echo sequences that show 
blood  as bright. Gradient echo sequences used for cardiac MRI include 
turbo FLASH and true FISP. A motion picture loop throughout the 
various phase of cardiac cycle can  also be  obtained in gradient 
sequences. Cine imaging is useful in functional assessment of ventricles. 
This sequences show signal intensity of moving blood as bright. 
Orthogonal planes ( axial , sagittal, coronal) used for general chest 
imaging are not suitable for cardiac imaging because cardiac axes are not 
parallel to the body axes. For morphology cardiac long axis views are 
done , function assessment short axis views are done. 
ECG gating is essential for motion free images of heart. Images are 
acquired in the particular phase of the cardiac cycle in every cardiac cycle 
to avoid images blur and cardiac motion artefacts. The phase of cardiac 
cycle during which images are acquired is decided by ECG gating. 
Usually R-wave is used to trigger the acquisition after some time delay 
such that data is acquired in the diastolic phase. Peripheral pulse can also 
be used for gating but it is less effective than ECG gating. 
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Two types of ECG gating(Joachim Lotz et al
20
) 
 Prospective gating 
 Retrospective gating 
 Prospective gating techniques – Before starting  data acquisition 
a signal is required . The time interval between trigger signal is 
called the arrhythmia rejection window . Example : Breath hold  
Phase-contrast sequences use this gating.  
 Retrospective gating techniques –No signal required data 
acquisition is done  throughout the  cardiac cycle. Later , this 
technique  retrospectively assign the data from the recorded trigger 
signals. It can  give information of the entire cardiac cycle.  
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Imaging planes include: 
1. Vertical long axis plane (two chamber view) 
2. Horizontal long axis view (four chamber view) 
3. Short axis plane 
4.  Five chamber plane 
5.  Right ventricular outflow tract plane 
 
IMAGING PLANES – CARDIAC MRI 
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Advantages of MRI (Raymond Benza et al
21
) 
 Unparalleled resolution 
 Three-dimensional imaging capacity 
 Noninvasive 
 Ability to depict soft tissues 
 
Disadvantages of MRI 
 Long scan times 
 Artifacts including motion, respiratory, cardiac motion 
 Incompatibility with pacemakers, defibrillators, and aneurysm clips 
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MR PHASE CONTRAST STUDY 
“With the increasing power of MR imaging units and the reduced 
time needed to complete a cardiac study, more and more indications are 
evolving for use of phase-contrast flow measurements as an additional 
source of quantitative functional information in cardiac MR imaging.” 
(Sakuma H et al
22
) 
Phase contrast study includes ‘through plane’ and ‘in plane’ 
imaging. Basic technique behind phase contrast study is contrast between 
the flowing blood & stationary tissues by manipulating the change in 
phase of magnetisation, such that phase of magnetisation from stationary 
spins is zero and phase of magnetisation from spins that are in movement 
wil be non-zero. Depending on how far the magnetisation ahead from the 
time it is tipped in to transverse plane until the time it is detected. 
“Hunter C. Champion etal23 conducted studies using the phase-
contrast technique and velocityencodedMRI showed the feasibility of 
estimating right-sidehemodynamics, but the ease of Doppler 
echocardiographyhas limited the enthusiasm of proceeding with large-
scalevalidation studies.” 
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In this technique signal intensity acquired is linearly proportional 
to the velocity of the spins. Rapidly moving spins will produce higher 
signal thus spins moving in one direction give bright signal and spins 
moving in opposite direction give dark signal. By this technique vascular 
structures can be identified and imaging can be done. Speed and direction 
of flowing blood is determined qualitatively. Quantitative analysis like 
velocity of the blood, volume of the flow rate can be measured using 
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phase difference images. Cross sectional imaging   of the vessel allows to 
measure the area of the  vessel. 
Volume of flow rate  =  Area x Average velocity 
 Velocity measurement in phase contrast study is sensitive to 
particular range of velocities. So we have to specify particular range of 
velocity for particular studies. It  is assigned by a term called Venc,  
velocity encoding value. Assigning the Venc value is very critical 
because if we assign the Venc value too low it will produce aliasing and 
can be misinterpreted in the image, thus choosing Venc value is very 
important. 
Phase shifts are measured in terms of degree and usually range 
within -/+ 180 degree.  
 =  . m .  
 - Phase difference 
 - Gyromagnetic ration 
m– Difference in the first moment of gradient time  
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Phase difference depends on 
 Gyromagnetic ratio  
 Difference in the first moment of gradient time  
 Velocity 
Venc is measured in terms of centimetre/sec. It ranges between 
highest and lowest detectable velocity for example if Venc = 75 cm/sec 
describes range of velocity between  +/-  75 cm/sec. 
Once Phase contrast MR images were acquired they post processed 
using a software ( in Siemens it is called Argus). ECG gating is done for 
the patient which  monitors heart rate also. 
 The parameters that are measured in Phase contrast study are  
(Lotz et al
24
) 
1. Peak  velocity 
2. Average velocity 
3. Maximum area of vessel (in cross section) 
4. Minimum area of vessel 
5. Average area of vessel 
6. Strain  
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7. Acceleration time (AT) 
8. Ejection time (ET) 
9. AT/ET ratio 
10. Average velocity during AT 
11. Average velocity during ETS 
 
 
PHASE CONTRAST FLOW VELOCITY IMAGING 
In plane imaging    :  Flow qualitative assessment  
Through plane imaging  :  Flow quantification 
A.  B. 
 
  
A. In plane imaging 
B. Through plane imaging 
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Though phase contrast MR imaging is very important role in  
quantitative information on blood flow , there are few common errors like 
mismatched velocity encoding either too high or too low , devaiation of 
imaging plane, inadequate spatial and temporal resolution, spatial mis-
registration, phase offset errors. However these errors can be reduced by 
appropriate method and technique . Flow  quantification usually done in 
the plane perpendicular to the vessel and the sequence should be repeated 
more than once with an higher Venc initially. 
“Flow measurements done  in vivo are  based on results of 
phantom studies” (Bakker CJ et al25). “Using phase-contrast 
measurement, Evans et al
26
 found a 5% difference between flow in the 
ascending aorta and flow in the pulmonary artery in healthy volunteers. A 
deviation from the true flow of 3.5%–4.5% was estimated as the inborn 
technical error of phase-contrast measurement when a non–breath-hold 
cine gradient-echo sequence with prospective gating is used”. Kondo et 
al
27 “found similar deviations between flow in the aorta and flow in the 
pulmonary trunk. Using retrospective gating and a breath-hold sequence 
(FastCine PC; GE Medical Systems, Milwaukee, Wis), we found a 3% 
difference between flow in the ascending aorta and flow in the pulmonary 
artery with an intraobserver variability of 2% and interobserver 
variability of 3%”  
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Phase-contrast techniques is superior to Doppler ultrasound in 
terms of  measurement of mean flow. However, MR imaging can assess 
the variation of flow within the vessel in a given spatial resolution. 
(28,29, 30) 
ERRORS AND LIMITATIONS INCLUDE 
 Encoding velocity too low 
 Encoding velocity too high 
 Inadequate spatial resolution . 
 Accelerated flow & spatial misregistration 
 Inadequate temporal resolution 
 Deviation of imaging plane 
 Phase offset errors 
Encoding Velocity Too High 
Encoding velocity too high will produce  noise. Noise in the 
velocity depends on  velocity encoding value and signal to noise ratio 
(SNR). It is directly proportional to the velocity encoding and inversely 
proportional to the signal to noise ratio. 
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Noise in velocity images increases as Venc values increase.Noise 
in a velocity decreases with  increased signal to noise ratio. An increased 
SNR is achieved by optimizing  parameters like flip angle,section 
thickness, time to echo. But increasing the time to echo might makes the 
sequence more prone to movement  artifacts. 
Encoding Velocity Too low 
 Encoding Velocity Too low will produce aliasing. It is a wrap 
around of velocity within a particular voxel. It can affect the results of the 
flow measurement drastically. But it ie easiest error to be identified and 
to be corrected. Using some software it can be corrected , however it is 
more effective to repeat the flow measurtement with a different  velocity 
encoding than to correct the  data that is aliased. 
Deviation of imaging plane 
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Measurements of flow are accurate if the imaging plane is 
orthogonal to the direction of flow. “Quantification of flow is done in  
through-plane imaging. In-plane imaging is not  used for estimation of 
flow because of increased partial volume effects. Deviation of  +/-15° 
from the orthogonal  plane is adjustable for estimation of flow , as the 
increase in vessel area is compensated  by the increase in partial volume 
effects.” 
Inadequate Temporal Resolution 
“Cardiac-gated flow measurement has a set of frames  each of 
which few show the anatomy and  others show the velocity information at 
a different  time in cardiac cycle”.  
Number of frames to be reconstructed is assigned by the imaging 
unit and it  cannot be altered by the user, like breath hold sequence. 
Usually  a value of 30 frames is sufficient for  post-processing time. 
Inadequate Spatial Resolution  
“When the pixel size exceeds one-third of the vessel diameter 
Significant partial volume effects must be expected (Tang C et al
31
). For 
a vessel diameter of 3.8 mm for a normal  anterior descending branch of 
the left coronary artery (Leung WH et al
32
), an in-plane resolution of 1.2 
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mm is required”. Partial volume effects canunder estimate  peak velocity 
with decreasing spatial resolution. However when flow or peak velocity 
is measured in the great vessels, this error usually does not occur. 
Accelerated Flow and Spatial Misregistration  
 Phase-contrast measurements are generally standardised for linear 
flow. In case of turbulence or stenotic jets producing accelerated flow  
causes the precision of the flow measurement to decline (Hoogeveen RM 
et al
33
),however this error can be corrected decreasing echo time 
(Mohiaddin RH et al
34
).  
Great vessels like ascending or descending aorta will cause severe 
problem of constant pulsation artefact along  the phase-encoding 
direction. 
Phase Offset Errors  
It  is due to phase error of moving as well asstationary spins. The  
phase offset error  dependent on gradient imbalance  and magnetic field 
in homogeneities . “It may be detected if the soft-ware for analysis 
supports a profile representation of the velocity images. In some cases, it 
may be compensated for by thoroughly applied back-ground subtraction” 
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PULSATION ARTIFACT 
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 Guidelines forMeasurement and Data Analysis (Lotz et al
35
) 
As mentioned earlier, flow measurements are more accurate if the 
flow encoding is set to through-plane flow  and if the imaging plane is at 
right angles to the vessel of interest. Generally the option of 
reconstructing the components of flow is done separately in each of the 
three imaging axes s in-stead of producing one summarized data set 
comprising the net through-plane flow.  
“To minimize partial volume effects section thickness of 7 mm 
used but maintain a good signal to noise ratio in the magnitude image. 
For small vessels like the coeliac, thickness decreased to adjust the partial 
volume effects to the small diameter. The choice of the matrixand field of 
view is   related to the anatomy”.  
“The sequence has to be repeated at least once for precise flow 
measurements. First measurement, use a high Venc and  quick analysis of 
the data will give an idea of the peak velocities in the vessel. Adding 10%  
to the high velocity prior will  account the physiologic variation of the 
peak velocity during measurement. This  is mandatory for estimation of 
peak velocities.” 
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In magnitude images the arteries should be round, check for 
appropriate vessel contour , and look for phase overlap artifacts. Always 
the images used to prescribe a phase-contrast measurement should be 
documented, so as to retrospectively look for errors if any. 
“Special software programs usually support the drawing of 
contours (ROIs) into the vessel of interest they automatically copy image 
the contours from velocity tomagnitude images and vice versa. For  large 
vessels like the aorta or pulmonary vessels the automatic contour 
detection works reasonably well.” 
A small ROI within the vessel is sufficient for estimation of the 
peak velocity,  it will give better results than a ROI encompassing the 
entire vessel, as arbitrary phase values in the tissue adjacent to the vessel 
are well avoided (Hamilton CA et al
36
). 
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Background Compensation  
 In  phase-contrast flow analysis  with availability of commercial 
software package , we can do background subtraction. 
 The background area should be  large , so as to perform 
background subtraction with out affect the image quality. 
 The mean phase information  is subtracted from the area of the 
vessel.  
 It should be in close proximity to the ROI. 
 These criteria  are difficult to maintain within the heart or 
mediastinum but easy to maintain in the abdomen or extremities 
imaging. 
 Though it is a powerful tool, it should be used with great caution, 
so as to avoid phase errors. 
 Generally  background compensation is to be avoided and limit its 
use to the rare cases. 
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FLOW PARAMETERS AND PULMONARY HYPERTENSION 
“In study conducted by Bouchard A et al37 that the average 
velocity of PA flow was the most useful single parameter in the 
evaluation of PAH. The presence of slow pulmonary flow in patients with 
PH was observed in early investigations by using spin-echo MR 
techniques”.  
“An average velocity cut off value of 11.7 cm/s revealed 
pulmonary arterial hypertension with 92.9% sensitivity and 82.4% 
specificity (Javier Sanz et al
38
).In patients with chronic PAH, a variety 
of flow measurements in the pulmonary trunk evaluated with phase-
contrast MR imaging correlate with the degree of hemodynamic 
disturbance as determined with the level of pulmonary pressures and 
vascular resistance. The average blood velocity throughout the cardiac 
cycle is strongly correlated with pulmonary pressures and resistance and 
appears to have consistent performance across different subgroups of 
patients”. 
“PA area in detecting the presence of PAH (sensitivity and 
specificity of 92.9% and 88.2%, respectively).However, the use of PA 
areas had some limitations, including inconsistent performance and more 
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difficult contour tracing in diastole when proton inflow (and therefore 
blood signal intensity) was lower .”(Laffon E et al39) 
SPECIFIC PROTOCOLS  
 
Use of minimum values for  time to repeat  and  time to echo  
improves the temporal resolution. Therefore, to control excessive noise in 
the images it i necessary to increase the echo time  depending on the MR 
imaging system used. 
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SVC and Inferior Vena Cava 
“For the first measurement the encoding velocity for flow 
measurement is 110 cm/sec. The usual velocity for peak velocity is 50–
80cm/sec. For the SVC, the imaging plane is selected below the influx of 
the azygos vein, with the azygos vein seen in the magnitude image.  
For magnitude imaging of the inferior vena cava (IVC), imaging 
plane is selected above the hepatic vein influx. The imaging should cover 
the ventral wall of the IVC”.  
Ascending Aorta 
“The encoding velocity for the first measurement for flow 
measurement is 200 cm/sec. The usual velocity for peak velocity 
measurement is 100–160 cm/sec choice of the localizer for the pulmonary 
trunk is crucial. It sometimes helps to choose a plane in the right 
ventricular outflow tract to visualize the pulmonary valve and pulmonary 
bifurcation”.  
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Pulmonary Arteries 
“The encoding velocity for the first measurement for flow 
measurement is 200 cm/sec. The usual velocity for peak velocity 
measurement is 60–120cm/sec.” 
“In a healthy adult, 55% of pulmonary flow goes through the right 
pulmonary artery and 45% goes through the left pulmonary artery”(Henk 
CB et al
40
). 
Small Intracardiac Structures  
 Spatial resolution and temporal resolution are the most important 
sources of errors for small structures like shunts, grafts, bypasses 
 Qualitative flow curve estimation is usually performed for even 
very small structures.  
 Because of their complex movement of coronary arteries and the 
coronary sinus pose an additional problem (Clarke GD et al
41
). 
 Retrospective cardiac gating and interpolation can produce more 
than 30 frames per cardiac cycle in a single breath hold. 
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  Use of phased-array coil for image reconstruction allows  
reduction of the field of view to about 22–24 cm without 
significant artifacts  
 “Whenever measurements are performed in a breath hold, one 
should keep in mind that a pro-longed breath hold affects 
hemodynamics and may alter results even for qualitative 
measurements”. 
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Main pulmonary artery 
 
 
IMAGING PLANE FOR MAIN PULMONARY ARTERY 
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“The encoding velocity for the first measurement for flow 
measurement is 180 cm/sec. The usualvelocity for peak velocity 
measurement is 60–120cm/sec. 
Use an oblique localizer on an axial or coronal image to visualize 
the natural bowing of the pulmonary artery . On the resulting image, 
select an imaging plane above the pulmonary valve but below the 
pulmonary bifurcation”.  
          “Phase contrast MRI has been used to study hemodynamic changes 
associated with PAH. In a recent study of 25 patients with PAH, mean 
pulmonary artery (PA) peak flow velocity, PA blood flow, and PA 
distensibility were found to be significantly lower than in a matched 
group of volunteers (p _ 0.002, p _ 0.002, and p _ 0.008, respectively) 
(Schwitter J et al
42
). This study also documentedreduced time to peak 
PA velocity and steeper velocity increase gradient among PAH patients. 
Another study compared fast-gradient echocardiographic phase-contrast 
MRI and radionuclide lung perfusion for assessing differentialbranch 
pulmonary blood flow in 12 children with suspected unilateral branch 
pulmonary artery stenosis.” (Hundley WG et al43). 
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Parameters of Pulmonary Hypertension by Noninvasive Imaging 
Method (Sallach SM et al
44
) 
 
 
Parameter 
Noninvasive 
Imaging 
Method of Choice 
Optimal View or Imaging 
Window 
Anatomy 
Pulmonary artery size 
 
cMRI 
 
High axial image 
Qualitative RV size, 
hypertrophy, trabeculations 
Echocardiography Apical 4-chamber, 
parasternal long-axis 
4-chamber, short-axis 
series for volumes, 
function, and masses 
Quantitative RV size, mass, 
trabecular mass 
cMRI  
Function 
RV free wall motion 
cMRI 4 chamber shortaxis view 
Interventricular septal motion  
 
Qualitative systolic function 
 
Quantitative systolic function  
 
Diastolic function  
 
cMRI 
 
Echocardiography 
 
cMRI 
 
Echocardiography 
echocardiography  
4-chamber, short-axis 
4-chamber , parasternal 
short-axis 
 
Short-axis series 
 
AV valve inflow 
parameters, tissue Doppler 
Hemodynamics  
Pulmonary valve motion 
RVOT flow 
Pulmonary artery pressure 
 
Echocardiography 
Echocardiography 
Echocardiography 
 
 M-mode 
pulse wave doppler 
TR,PR velocities any flow 
in to right heart 
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Current Issues in Cardiovascular Magnetic Resonance Imaging 
 
 Large number of technical parameters that the scanner operator 
needs to know 
 Large number of parameter choices results in different imaging 
sites using protocols with different parameters, making a 
comparison of images difficult 
 Intensive training is required for scanner operators 
 Lack of a standardized viewing and reporting format 
 Imaging centers have to create their own viewing tools 
 Viewing takes so much time that it limits patient throughput 
 Lack of a standardized nomenclature for magnetic resonance 
sequences and parameters 
 Vendors choose different names for the same or similar techniques 
to differentiate them from their competitors 
 Focus on research 
 Small number of current procedural terminology codes, each with 
limited scope 
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 Current procedural terminology codes have not kept up with 
technological developments 
“In a study conducted by Sanz et al45 the minimum PA area was 
useful in detecting the presence of PAH (sensitivity and specificity of 
92.9% and 88.2%, respectively). And  average velocity of PA flow was 
the most useful single parameter in the evaluation of PAH. The presence 
of slow pulmonary flow in patients with PH was observed in early 
investigations by using spin-echo MR techniques (Bouchard et al
46
) or 
velocity mapping (Bogren et al
47
). In a group of 33 patients with chronic 
thromboembolic disease, PA peak velocity had a moderate correlation(r _ 
0.60) with mPAP (Kreitner KF et al
48
). There  results in a larger group 
of patients with PAH confirm a significant though weaker correlation 
between peak velocity and pulmonary pressures and resistance, whereas 
average velocity had the best correlations with hemodynamic 
measurements (r ranging from _0.73 to0.86). These findings suggest that 
as pulmonary pressures and resistance increase, the circulation of blood 
through the pulmonary vascular bed is globally hampered and 
progressively slows. A potential role for the quantification of average 
velocity at peak systole in PH evaluation has been previously suggested 
(laffon E et al
49
). However this is the first investigation to evaluate 
average velocity during the complete cardiac cycle.” 
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“In a  study by Fine et al50 on use of RV strain imaging to risk 
stratify patients with pulmonary hypertension in the absence of 
pulmonary venous hypertension promises to extend the usefulness of 2D 
echo in this setting at the present time. However, it remains uncertain 
whether this will lead to the desired result in the long term: a definitive 
method for prediction of outcomes in pulmonary hypertension. Nor is it 
clear whether progress in application of 3DRV or 2D knowledge-based 
volumetric imaging will super cede it or whether advances in image-
based evaluation of RV loading conditions will permit meaningful 
assessment of RV contractility in the future.” 
 With the advent of cardiac MRI around 1980s which led to rapid 
development of volumetric 3D imaging for left ventricular (LV) size, 
function, and mass followed by assessing 3D LV strain which considered 
as  gold standards in the cardiovascular armamentarium. But even so, 
imaging of RV volume and mass remained more reliable whereas RV 
free wall strain assessment remained elusive with CMR until now. Now 
with the emergence of echo RV free wall strain imaging has recognised. 
( Shehata ML et al
51
) 
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Metrics that were directly measured in all vessels in phase contrast 
study were forward-flow volume(FFV) and backward-flow volume 
(BFV); all other metrics were calculated as follows: 
1.  Pulmonary forward flow volume (PFFV)=RPA FFV+LPA FFV, 
2.  Pulmonary backward flow volume (PBFV)=RPA BFV+LPA BFV, 
3.  Net pulmonary flow volume (NPFV)=PFFV−PBFV, 
4.  Pulmonary artery regurgitation fraction (PRF)=(PBFV/ 
PFFV)×100, 
5.  Tricuspid valve regurgitation fraction (TRF)=(RVSV−PFFV/ 
RVSV)×100.13 
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AIM OF THE STUDY 
1. To assess the pulmonary arterial flow parameters measured using 
phase contrast magnetic resonance imaging (MRI) 
2. To correlate the size of the main pulmonary artery as measured 
using spiral computerised tomography (CT) with the flow 
parameters as measured using phase contrast MRI and also with 
ECHO parameters. 
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MATERIALS AND METHODS 
 
STUDY DESIGN   : PROSPECTIVE OBSERVATIONAL 
PLACE OF STUDY :BARNARD INSTITUTE OF RADIOLOGY,   
  RAJIV GANDHI GOVERNMENT  
  GENERAL HOSPITAL, CHENNAI 
DURATION OF STUDY  : 6 MONTHS 
STUDY SIZE  :  50 PATIENTS 
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STUDY POPULATION 
INCLUSION CRITERIA: 
 Age more than 20years 
 The patients who are found to have dilated main pulmonary artery 
(2.9cm) in CT chest study. 
 Those patients who are admitted with  pulmonary hypertension of 
various etiology were evaluated  
 Those patients who suspected to have pulmonary hypertension 
  subjects with normal pulmonary artery  diameter are also included 
in the study, with no history of chronic lung disease or heart 
disease 
EXCLUSION CRITERIA 
 Patients with pace maker, metallics implants, clips for intracranial 
aneurysm 
 Patients having claustrophobia 
 Pregnant patients 
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 Patients who  are sick 
 Patients with acute pulmonary thromboembolism. 
STUDY PROCEDURE 
OUTLINE 
 After informed written consent, all patients underwent MRI Phase 
contrast flow velocity imaging  including in plane and through 
plane imaging. 
 With  Mean VENC value  for main pulmonary artery 75-100 
cm/sec 
 Post processing done with a commercial software ARGUS 
 Patients ECHO findings reviewed. 
 Control subjects underwent CT chest followed by MRI phase 
contrast imaging and ECHO 
MACHINE : 
Studies were performed with  
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 1.5-T clinical magnet Magnetom symphony; Siemens Medical 
Solutions, Erlangen, Germany. 
 CT scanner TOSHIBA (Asteion) 
After evaluating the pulmonary artery size in contrast enhanced CT 
chest study, the patients are examined whether they  are in sinus rhythm  
and they are made to liecomfortably in  supine position. Phasedarray 
surface coil  is used as a receiver. ECG leads (3 in number)  are attached 
to the patients chest in the posterior aspect. The patients are instructed to 
perform end-expiratory breath holds precededby brief hyperventilation. 
After  acquiring Standard localizer views , axial four chamber view of the 
heart is acquired. Then  two double-obliqueviews oriented along the main 
axis ofthe pulmonary trunk were acquiredwith a standard steady-state 
free precession cine MR sequence . The imaging plane should be  
perpendicular tothe main PA for the acquisition ofphase-contrast MR 
images. 
Phase-contrast MR images were acquiredwith a segmented fast 
gradientecho MR sequence , with velocityencoding perpendicular to the 
imagingplane and with velocity encoding of  75 – 100 cm/sec. In 
Contrast enhanced CT CHEST transverse diameter of the the main 
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pulmonary artery is measured in axial sections at about 2cm proximal to 
its bifurcation in to right and left pulmonary artery. 
 
 
 
 
       ECG LEADS 
  
ECG CONNECTOR 
PHASED ARRAY COIL 
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MRI 
1.5 TESLA CLINICAL MAGNET, MEGNETOM SYMPHONY (SIEMENS) 
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DATA INTERPRETATION AND ANALYSIS 
MRI PA FLOW PARAMETERS 
1. Average velocity 
2. Average pulmonary artery area 
3. Peak velocity 
4. Maximum pulmonary artery area 
5. Minimum pulmonary artery area 
CT  
1. Size  of the  main pulmonary artery  
 ECHO  
1. TRPG 
2. TAPSE 
3. Presence or absence of A wave in the M mode. 
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PARAMETERS CUT OFF VALUES 
ECHO  
1.TRPG Less than 25mmHg - normal 
2. ‘a’ wave Present - normal 
3.TAPSE More than 20mm- normal 
 
 
CT 
 
1. PA size Less than 2.9cm - normal 
 
 
MRI 
 
1.Average PA  velocity More than 11.7cm/sec - normal 
2.Minimum PA area Less  than 10.5cm
2
 - normal
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CASE 1 
Clinical history: 
No specific complaints 
Not a known case of congenital heart disease. 
ECHO FINDINGS: 
       TRPG:   22 mmHg                           TAPSE: 2.2 cm 
 
 
 
 
 
 
 
 
 
‘a’ wave  present 
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CT:  
Main pulmonary artery size: 2.42 cm 
 
 
MRI:  
Cardiac MRI – TRUFI coronal 
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PHASE CONTRAST FLOW STUDY 
          In plane imaging                                  Through plane imaging 
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PULMONARY ARTERY  FLOW PARAMETERS 
 
 
 
 
 
 
 
 
 
 
 
 
Average velocity: 19.85 cm/sec 
Minimum  pulmonary artery (PA) area: 3.88 cm
2
 
 
DIAGNOSIS : NORMAL STUDY 
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CASE 2 
Clinical history: 
Complaints of breathlessness on & off for past 6 months. 
Not a known case of congenital heart disease. 
ECHO FINDINGS: 
        TRPG:   31.1 mmHg          TAPSE: 2.0 cm 
 
 
 
 
                                                 Absent ‘a’ wave                
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CT:  
Main pulmonary artery size: 3.56 cm 
 
 
 
 
 
MRI:  
  Cardiac MRI – TRUFI coronal 
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PHASE CONTRAST FLOW STUDY 
     In plane imaging                                       Through plane imaging 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
87 
 
 
 
PULMONARY ARTERY  FLOW PARAMETERS 
 
Average velocity: 8.09 cm/sec 
Minimum  pulmonary artery (PA) area: 12.26 cm2 
DIAGNOSIS : PULMONARY ARTERIAL HYPERTENSION 
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 CASE 3 
Clinical history: 
Complaints of breathlessness on & off for past 6 months. 
Not a known case of congenital heart disease. 
ECHO FINDINGS: 
TRPG:   39.3 mmHg                                  TAPSE: 2.21 cm 
 
 
 
 
 
                                                 Absent ‘a’ wave                
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CT:  
Main pulmonary artery size: 3.64 cm 
 
MRI:  
Cardiac MRI – TRUFI coronal 
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PHASE CONTRAST FLOW STUDY 
Through plane imaging 
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PULMONARY ARTERY  FLOW PARAMETERS 
 
 
 
 
 
 
 
 
 
Average velocity: 11.36 cm/sec 
Minimum pulmonary artery (PA) area: 12.20 cm2 
 
DIAGNOSIS : PULMONARY ARTERIAL HYPERTENSION 
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CASE 4 
Clinical history: 
Complaints of breathlessness on & off for past 1 year. 
Not a known case of congenital heart disease. 
ECHO FINDINGS: 
TRPG:   36 .0 mmHg                                      TAPSE: 2.0 cm 
 
 
 
 
                                                 Absent ‘a’ wave                
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CT:  
Main pulmonary artery size: 3.7 cm 
 
 
 
 
 
 
 
 
 
 
 
MRI:  
Cardiac MRI – TRUFI coronal 
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PHASE CONTRAST FLOW STUDY 
      Through plane imaging              In Plane imaging  
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PULMONARY ARTERY  FLOW PARAMETERS 
 
 
 
 
 
 
 
 
 
 
 
 
Average velocity: 7.53 cm/sec 
Minimum  pulmonary artery (PA) area: 14.37 cm
2 
 
DIAGNOSIS : PULMONARY ARTERIAL HYPERTENSION 
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STATISTICAL ANALYSIS 
TABLE 1 
  FREQUENCY PERCENT 
 FEMALE 22 44.0 
MALE 28 56.0 
Total 50 100.0 
 
         
 
Among 50 total subjects, 22 subjects were female and 28 subjects 
were male. That is 44% are female  and 58% are male. 
44% 
56% 
SEX DISTRIBUTION 
FEMALE MALE
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TABLE 2 
 
 Frequency Percent 
15 TO 30 16 32.0 
31 TO 45 20 40.0 
46 TO 60 14 28.0 
Total 50 100.0 
 
 
 
In this study, out of 50 subjects,  16 (32%) subjects were in the age  
group of  15 to 30, 20 (40%) subjects were in the age group of 31 to 45 
remaining 14(28%) subjects fall in the age group of 46 to 60. Thus the 
frequency is slightly higher in the age group 31 to 45. 
0
5
10
15
20
25
30
35
40
15 TO 30
31 TO 45
46 TO 60
32 40 
28 
AGE DISTRIBUTION 
Series1
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TABLE 3 
                                 PULMONARY ARTERY SIZE 
PA size Frequency Percent 
< 2.9 cm 13 26 
> 2.9cm 37 74 
 Total 50 100 
   
 
 
 
 
In this study, out of 50 subjects, 37 (74%) subjects were having PA 
size more than 2.9cm, 13 (26%) subjects were having PA size less than  
2.9cm. 
 
 
0
10
20
30
40
50
60
70
80
>2.9 CM <2.9 CM
74 
26 
CT SIZE % (n=50) 
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TABLE 4 
PA AVERAGE VELOCITY 
Average PA 
velocity (cm/sec) Frequency Percent 
 
< 11.7  
 
10 
 
20 
> 11.7 40 80 
 Total 50 100 
   
 
 
 
In this study, out of 50 subjects, 40 (80%) subjects were  having a 
velocity of  < 11.7 cm/sec, 10 (20%) subjects were having a velocity of  
>11.7 cm/sec. 
 
  
0
10
20
30
40
50
60
70
80
<11.7  CM >11.7 CM
80 
20 
MRI AVERAGE VELOCITY % (n=50) 
100 
 
TABLE 5 
 PA MINIMUM AREA 
Minimum PA 
area  ( cm
2 
)
 
Frequency Percent 
<10.5  15 30 
> 10.5 35 70 
           Total  50 100 
   
 
 
 
In this study, out of 50 subjects, 35 (70%) subjects were  having a 
minimum area of  >10.5 cm
2
, 15 (30%) subjects were having a minimum 
area of  <10.5 cm
2
. 
>10.5 CM
<10.5 CM
70 
30 
MINIMUM PA AREA % (n=50) 
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CORRELATION CHART 
 
 
 CT SIZE 
MRI 
AVEREAGE 
VELOCITY 
MRI 
AVERAGE 
AREA 
TRPG 
CT SIZE Pearson Correlation 1 -.865
**
 .806
**
 .716
**
 
Sig. (2-tailed)  .000 .000 .000 
N 50 50 50 50 
MRI AVEREAGE 
VELOCITY 
Pearson Correlation -.865
**
 1 -.895
**
 -.810
**
 
Sig. (2-tailed) .000  .000 .000 
N 50 50 50 50 
MRI MINIMUM AREA Pearson Correlation .806
**
 -.895
**
 1 .768
**
 
Sig. (2-tailed) .000 .000  .000 
N 50 50 50 50 
TRPG Pearson Correlation .716
**
 -.810
**
 .768
**
 1 
Sig. (2-tailed) .000 .000 .000  
N 50 50 50 50 
**. Correlation is significant at the 0.01 level (2-tailed). 
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GRAPH 1 
 
 
 
This graph shows correlation between PA Average velocity with 
pulmonary artery size. It has a negative correlation with Pearson 
correlation value of – 0.865 with P value  0.001 (P value < 0.05). The 
percentage of correlation of 86.5%. 
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GRAPH 2 
 
 
 
This graph shows correlation between PA area with pulmonary 
artery size. It has a positive correlation with Pearson correlation value of 
0.806 with P value 0.001 (P value < 0.05). The percentage of correlation 
of 80.6% 
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GRAPH 3 
 
 
This graph shows correlation between TRPG with pulmonary 
artery area. It has a positive correlation with Pearson correlation value of 
0.716 with P value 0.001 (P value < 0.05). The percentage of correlation 
of  71.6% 
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GRAPH 4 
 
 
This graph shows correlation between PA  area with PA average 
velocity. It has a negative correlation with Pearson correlation value of – 
0.895 with P value  0.001 (P value < 0.05). The percentage of correlation 
of 89.5%. 
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GRAPH 5 
 
 
This graph shows correlation between TRPG with PA average 
velocity. It has a negative correlation with Pearson correlation value of – 
0.810 with P value  0.001 (P value < 0.05). The percentage of correlation 
of 81%. 
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DISCUSSION 
Out of 50 subjects who underwent phase contrast flow velocity 
imaging 22 subjects were female and 28 were male. With regard to the 
CT criteria of pulmonary artery size, 37 out of 50 subjects had size more 
than 2.9cm and remaining 13 subjects had less than 2.9cm. 34 subjects 
had TRPG value more than 25mmHgand remaining 16 subjects had less 
than 25mmHg. In MRI phase contrast flow velocity imaging 40 subjects 
had average velocity less than 11.7cm/sec & minimum area more than 
10.5cm
2
  and remaining  10 subjects had average velocity more than 
11.7cm/sec & average area less than 10.5cm
2
. All 37 subjects who had  
pulmonary artery size more than 2.9cm including 34 subjects who had 
TRPG > 25mmHg  who were diagnosed and treated as pulmonary 
hypertension depending on clinical symptoms and investigations( ECHO 
and CT ) either in combination or in isolation were having average 
velocity less than 11.7cm/sec. 
 All 37 subjects who had  pulmonary artery size more than 
2.9cmincluding 34 subjects who had TRPG > 25mmHg  had average 
velocity less than 11.7cm/sec and average pulmonary artery area more 
than 10.5cm
2
. Thus pulmonary artery size criteria >2.9cm which is 89% 
sensitive and 82 specific for diagnosis of  pulmonary hypertension is well 
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correlated with average velocity and minimum area of the pulmonary 
artery as measured using phase contrast MRI. 
 Among 50 total subjects, 22 subjects were female and 28 subjects 
were male. That is 44% are female and 58% are male. 
In this study, out of 50 subjects, 16 (32%) subjects were in the age  
group of  15 to 30, 20 (40%) subjects were in the age group of 31 to 45 
remaining 14(28%) subjects fall in the age group of 46 to 60. 
In this study, out of 50 subjects, 37 (74%) subjects were having PA 
size more than 2.9cm, 13 (26%) subjects were having PA size less than 
2.9cm. out of which 34 had corresponding ECHO correlation but 3 
subjects had a normal echo finding. 
In this study, out of 50 subjects, 40 (80%) subjects were having a 
velocity of < 11.7 cm/sec, 10 (20%) subjects were having a velocity of  
>11.7 cm/sec. Thus out of 40 subjects positive for pulmonary 
hypertension in MRI , 37 subjects had corresponding  correlation with 
pulmonary artery size more than 2.9cm suggesting pulmonary 
hypertension. 
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In this study, out of 50 subjects, 35 (70%) subjects were  having a 
minimum area of  >10.5 cm
2
, 15 (30%) subjects were having a minimum 
area of  <10.5 cm
2
. 
Graph 1 shows correlation between PA Average velocity with 
pulmonary artery size. It has a negative correlation with pearson 
correlation value of – 0.865 with P value of 0.001 (P value < 0.05). The 
percentage of correlation of 86.5%. As PA size increases pulmonary 
artery  average velocity decreases. 
Graph 2 shows correlation between PA minimum area with 
pulmonary artery size. It has a positive correlation with Pearson 
correlation value of  0.806 with P value of 0.001 (P value < 0.05). The 
percentage of correlation of 80.6%.  As  PA size increases PA average 
area also increases. 
Graph 3 shows correlation between TRPG with pulmonary artery 
size. It has a positive correlation with Pearson correlation value of 0.716 
with P value of 0.001 (P value < 0.05). The percentage of correlation of 
71.6%. As pulmonary artery size increases TRPG value also increases. 
Graph 4 shows correlation between PA minimum area with PA 
average velocity. It has a negative correlation with Pearson correlation 
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value of – 0.895 with P value of 0.001 (P value < 0.05). The percentage 
of correlation of 89.5%. As the PA average area increases PA average 
velocity decreases. 
Graph 5 shows correlation between TRPG with PA average 
velocity. It has a negative correlation with Pearson correlation value of – 
0.810 with P value of 0.001 (P value < 0.05). The percentage of 
correlation of 81%. As the TRPG value increases PA velocity decreases. 
Thus as the pulmonary hypertension develops pulmonary artery 
size, minimum PA area, TRPG value increases and PA average velocity 
decrease. And the percentage of correlation (86.5%) is higher between  
increase PA size and decrease in velocity and also between PA minimum 
area and PA average velocity (89.5%). 
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RESULTS 
 Out of 50 subjects who underwent phase contrast flow velocity 
imaging 22 were male and 28 were female patients. 
 With regard to the CT criteria of pulmonary artery size more than 
2.9cm, 37 out of 50 subjects  had size more than 2.9cm and 
remaining 13 subjects had less than 2.9cm. Out of  which 34 
subjects had TRPG value more than 25mmHg and remaining had 
less than 25mmHg 
 In MRI phase contrast flow velocity imaging 40 subjects had 
average velocity less than 11.7cm/sec& minimum  area more than 
10.5cm
2
 and remaining  10 subjects had average velocity more 
than 11.7cm/sec & minimum area less than 10.5cm
2
 
 All  37 subjects who had  pulmonary artery size more than 2.9cm 
had average velocity less than 11.7cm/sec and minimum 
pulmonary artery area more than 10.5 cm
2 
, thus pulmonary artery 
size criteria for pulmonary hypertension is well correlated with PA 
average velocity and  PA minimum area of the pulmonary artery as 
measured using phase contrast MRI. 
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 Degree of correlation ( 86.5%) is higher for PA size & PA average 
velocity  and also between PA minimum area & PA average 
velocity (89.5%) 
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CONCLUSION 
 MRI Phase contrast imaging is a novel non invasive imaging 
modality that can be used in the diagnosis of pulmonary 
hypertension by means of measuring flow parameters of 
pulmonary artery. 
 Flow parameters like PA average velocity and PA minimum  
pulmonary area of  well correlated with the pulmonary  artery size . 
 Thus MRI phase contrast flow velocity imaging can be  safe and 
non invasive imaging modality of choice in pulmonary 
hypertension. 
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MASTER CHART 
S. 
No 
Name Age 
CT Size 
cm 
MR PA 
Velocity 
Cm/sec 
MR PA 
Area 
Cm
2 
TRPG 
mmHg 
1 Muthu 52 2.4 14.29 5.39 18 
2 Saranraj 41 2.3 14.15 5.29 22 
3 Ravi M 45 3.3 7.53 14.37 28 
4 Madhal 49 3.4 8.41 13.92 29 
5 Mufedol 28 3.4 8.39 13.87 28 
6 Malliga 32 2.6 15.1 5.32 17 
7 Alamelu 45 2.3 15.9 5.1 8 
8 Dhanalaskhmi 37 2.4 14.34 5.34 15 
9 Madhavan 45 3.1 11.09 10.57 29 
10 Nagaraj 51 2.9 11.34 12.2 30 
11 Chinathambi 48 3 11.14 12.46 31 
12 Natesan 48 3.1 11.12 12.51 28 
13 Pattabi 45 3.2 11 12.37 34 
14 Vendhan 27 2.4 14.61 5.67 21 
15 Veeramani 38 2.3 14.75 4.98 22 
16 Praveen 18 1.5 16.9 3.8 18 
17 Lakshmi 29 3.3 10.94 11.87 34 
18 Mufedol 44 3.4 10.81 12.34 36 
19 Muthukumar 30 2.9 11.44 12.59 29 
20 Ravi J 43  3 11.36 12.26 22 
21 Saranraj 37  3.1 11.24 10.31 24 
22 Chitra 19 3.1 11.16 10.98 23 
23 Madhavan 54 3.3 10.71 11.21 32 
24 Lakshmirani 34 3.4 10.89 9.84 38 
25 Sangeetha 32 2.2 7.98 14.87 44 
26 Munusamy 47 3.6 8.24 13.98 36 
27 Karunakaran 24 3.7 7.91 14.54 42 
28 Devan 40 3.7 7.84 14.37 46 
29 Mariyammal 48 3.1 10.51 12.8 29 
30 Rojapoo 53 3.3 10.94 13.41 31 
31 Jhanaki 52 2.1 15.83 6.94 21 
32 Vaiyammal 47 2.8 11.31 5.29 24 
33 Fiaki 39 2.7 11.27 5.86 22 
34 Ellammal 42 2.6 14.54 4.92 25 
35 Vadivel 48 3.5 8.51 13.96 32 
36 Elumalai 37 3.4 8.91 13.51 36 
37 Mythili 29 3.5 7.98 13.98 38 
38 Boopalan 34 3.8 7.54 14.01 43 
39 Neelambari 25 3.7 7.39 14.18 42 
40 Veeraraghavan 26 3.7 7.28 14.12 45 
41 Sathyaprakash 24 3.4 9.12 13.98 29 
42 Manikandan 51 3.3 8.43 13.47 28 
43 Chellan 29 3.2 9.04 14.01 29 
44 Ibrahim 28 3.8 6.54 15.67 33 
45 Valli 25 3.1 10.49 13.12 29 
46 Kumari 29 3.3 10.81 13.53 30 
47 Senguttuvan 34 3.2 9.26 13.96 31 
48 Sumathi 31 3.2 9.38 13.87 29 
49 Renuka 27 2.9 11.51 12.57 29 
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50 Periyapaiyan 49 3 11.21 13.1 32 
 
patients Information Sheet 
Title  : PHASE CONTRAST FLOW VELOCITY 
IMAGING OF MAIN PULMONARY ARTERY 
Site  : Barnard Institute of Radiology, 
Rajiv Gandhi Government General Hospital, 
Chennai – 600 003. 
 
PURPOSE OF THE STUDY 
 Pulmonary hypertension is uncommon disorder characterized by 
dilated main pulmonary artery. It is usually present as breathlessness and 
it can be asymptomatic at early stages. These symptoms may last for long 
period. We want to test the pulmonary artery in this condition. We have 
obtained permission from the Institutional ethical committee. 
The study is a non-invasive. No fasting is required for this 
procedure. You will be placed in MRI console and scan will be taken on 
you. It takes 15 mins for the completion of this procedure. No injection 
will be given to you and CT chest will be performed. If needed ECHO 
will be done. Single visit to Radiology department is enough. 
Before the procedure we will examine your RFT values which are 
essential for your safety. You must not participate if you are pregnant, 
127 
 
breastfeeding a child, or if you are of childbearing potential and not 
practicing effective methods of contraception (for studies/procedures 
which may harm the fetus). 
The results of the research may provide benefits to the society in 
terms of advancement of medical knowledge and/or therapeutic benefit to 
future patients. 
You have the right to confidentiality regarding the privacy of your 
medical information (personal details, results of physical examinations, 
investigations, and your medical history). By signing this document, you 
will be allowing the research team investigators, other study personal, 
sponsors, Institutional Ethics committee and any person or agency 
required by law like the Drug controller General of India to view your 
data, if required. 
The information from this study, if published in scientific journals 
or presented at scientific meetings, will not reveal your identity. 
Your decision not to participate in this research study will not 
affect your medical care or your relationship with the investigator or the 
institution. You will be taken care of and you will not lose any benefits to 
which you are entitled. 
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The participation in this research is purely voluntary and you have 
the right to withdraw from this study at any time during the course of the 
study without giving any reasons. However, it is advisable that you talk 
to the research team prior to stopping the treatment /discontinuing of 
procedures. 
 
 
Signature of Investigator   Signature of Participant 
Date       Date 
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Patient Consent Form 
Title of the Project 
PHASE CONTRAST FLOW VELOCITYIMAGING OF MAIN 
PULMONARY ARTERY 
Institution : Barnard Institute of Radio Diagnosis, 
Madras Medical College, 
Chennai-600 003.  
Name :     Date    : 
Age :     IP No    : 
Sex :     Project Patient No  : 
The details of the study have been provided to me in writing and 
explained to me in my own language. 
I confirm that I have understood the above study and had the 
opportunity to ask questions. 
I understood that my participation in the study is voluntary and that 
I am free to withdraw at any time, without giving any reason, without the 
medical care that will normally be provided by the hospital being 
affected. 
I agree not to restrict the use of any data or results that arise from 
this study provided such a use is only for scientific purpose(s). 
I have been given an information sheet giving details of the study. 
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I fully consent to participate in the above study regarding mean 
corpuscular volume as a marker of Alcohol use disorder. 
 
__________________________ 
Name of the Subject 
_____________ 
Signature 
___________ 
Date 
   
__________________________ 
Name of the Investigator 
_____________ 
Signature 
___________ 
Date 
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ABBREVIATIONS 
KEY WORDS:  
PAH  : Pulmonary arterial hypertension 
CT  : Computerised Tomography 
MRI  : Magnetic Resonance Imaging 
PA  : Pulmonary Aretry 
MPAP : Main Pulmonary Artery Pressure 
PCWP : Pulmonary Capillary Wedge Pressure 
TPG/TRPG :         Tricuspid Regurgitant Pressure Gradient 
TAPSE : Tricuspid Annular Plane Systolic Excursion  
PVH  : Pulmonary Venous Hypertension 
HRCT : High Resolution Computerised Tomography 
MPA  : Main Pulmonary Artery 
ILD      : Interstitial Lung Disease 
RCH  : Right Heart Catheterisation 
ECG            : Electrocardiogram 
Venc             : Velocity Encoding 
SNR   : Signal To Noise Ratio 
RVOT  : Right Ventricular Outflow Tract 
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PROFORMA 
Name : 
Age and sex : 
Weight                              : 
IP/ OP number : 
Ward number : 
Address : 
 
HISTORY: 
 
PAST HISTORY: 
 
INVESTIGATION: 
 
1.Serum creatinine 
2.Blood urea 
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DATA INTERPRETATION AND ANALYSIS 
MRI  PA FLOW PARAMETERS 
6. Average velocity 
7. Average pulmonary artery area 
8. Peak velocity 
9. Maximum pulmonary artery area 
10. Minimum pulmonary artery area 
CT  
2. Size  of the  main pulmonary artery  
ECHO  
4. TRPG 
5. TAPSE 
6. Presence or absence of A wave in the M mode. 
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